The downgrade from Buy to Neutral suggests that Citigroup sees less upside potential in Reata Pharmaceuticals, which could lead to some investors selling their shares. However, the increase in price target from $127 to $172.5 indicates that Citigroup still sees some value in the stock, which could attract some investors. The net effect on the stock price in the short term is uncertain, hence the neutral score.